Your browser doesn't support javascript.
loading
An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody.
Atanasoff, Kristina E; Brambilla, Luca; Adelsberg, Daniel C; Kowdle, Shreyas; Stevens, Christian S; Slamanig, Stefan; Hung, Chuan-Tien; Fu, Yanwen; Lim, Reyna; Tran, Linh; Allen, Robert; Sun, Weina; Duty, J Andrew; Bajic, Goran; Lee, Benhur; Tortorella, Domenico.
Afiliação
  • Atanasoff KE; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Brambilla L; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Adelsberg DC; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Kowdle S; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Stevens CS; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Slamanig S; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Hung C-T; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Fu Y; Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Lim R; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Tran L; Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.
  • Allen R; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Sun W; Sorrento Therapeutics, Inc., San Diego, California, USA.
  • Duty JA; Sorrento Therapeutics, Inc., San Diego, California, USA.
  • Bajic G; Sorrento Therapeutics, Inc., San Diego, California, USA.
  • Lee B; Sorrento Therapeutics, Inc., San Diego, California, USA.
  • Tortorella D; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
mBio ; 15(1): e0247723, 2024 Jan 16.
Article em En | MEDLINE | ID: mdl-38054729
ABSTRACT
IMPORTANCE The COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread so long as they recognize and interact with circulating variants. The epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone against many SARS-CoV-2 variants of concern were characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis and VSV-spike neutralization studies. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pandemias / COVID-19 Limite: Humans Idioma: En Revista: MBio Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Pandemias / COVID-19 Limite: Humans Idioma: En Revista: MBio Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos